博思清与氯氮平治疗单纯型精神分裂症疗效与安全性评价  

Efficacy and safety evaluation of aripiprazole and clozapine in the treatment of simple type schizophrenia

作　　者：毕见好 高丽静 

机构地区：[1]山东省威海市精神卫生中心,山东威海264205

出　　处：《转化医学电子杂志》2015年第4期53-54,共2页E-Journal of Translational Medicine

摘　　要：目的:对博思清与氯氮平治疗单纯型精神分裂症疗效与安全性进行评价.方法:研究对象选取本院2008-11/2014-12收治的100例符合ICD-10单纯型精神分裂症诊断标准的患者,按随机方法分为两组.博思清组患者采用博思清治疗,氯氮平组患者给予氯氮平治疗.治疗3个月和6个月分别采用PANSS量表减分率评价疗效,对比分析两组患者治疗效果和不良反应的差异性.结果:经过3个月治疗后氯氮平组患者总有效率与博思清组相当(P>0.05);而治疗6个月后博思清组治疗总有效率明显优于氯氮平组(P<0.05);两组患者治疗期间不良反应发生率有显著差异,博思清组发生率明显低于氯氮平组(P<0.05).结论:博思清和氯氮平治疗精神分裂症的近期效果相当,但从安全性和远期疗效来看,博思清有明显优势,安全性较高,值得推广.AIM：To evaluate the efficacy and safety of aripiprazole and clozapine in the treatment of simple type schizophrenia.MRTHODS： 100 cases of simple type schizophrenia meeting ICD-10 criteria were analyzed in our hospital from November 2008 to December 2014,and they were divided randomly into two groups. Aripiprazole group was treated with aripiprazol, while clozapine group was treated with clozapine. Using PANSS reducing rates evaluated the curative effect after 3 months and half a year, and the difference treatment effect and adverse reaction of two groups were analyzed. RESULTS：The total effective rate of two group was comparative after 3 months（P〉0.05）; and the total effective rate of aripiprazole group was better than clozapine group after half a year（P〈0.05）.The incidence of adverse reaction of two group had significant difference, and the incidence of adverse reaction of aripiprazole is lower than clozapine group’s（P〈 0.05）. CONCLUSION： The effect is relatively in recent of aripiprazole and clozapine in the treatment of simple type schizophrenia, but aripiprazole has obvious advantages for the long-term efficacy and safety. Its security is greater, and is worthy of promotion.

关 键 词：博思清 氯氮平 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]